## 2 Materials and Methods
### Synthesis of ligands
#### 2.2.8 2-(2-(2-(Pent-4-en-1-yloxy)ethoxy)ethoxy)ethyl-4-methylbenzenesulfonate **14**
The solution turned blue immediately, and after 10 min, a dry THF solution (1,4 mL) of the crude compound **17** was added. The reaction was stirred at \(-\)78 \({}^{\circ}\)C for 15 min, then powdered NH\({}_{4}\)Cl (\(\approx\)200 mg) was added and the reaction was warmed to r.t. The solvent was evaporated and the crude was subjected to reverse phase C18 chromatography (gradient eluent: H\({}_{2}\)O-MeOH); a total of 14 mg (0.032 mmol as monomer, 65% yield over two steps) of **18** was obtained. \({}^{1}\)H NMR (500 MHz, CD\({}_{3}\)OD) 8 4.11 (ddd, J = 11.6, 5.1, 2.7 Hz, 1H, H1), 3.79-3.58 (m, 18H, H2, H3, H4, H5, H6a,b, CH\({}_{2}\)CH\({}_{2}\)O-, 3.51 (t, J = 6.6 Hz, 2H, H7a,b), 3.23-3.18 (m, 1H, H2\({}^{\prime}\)a), 3.17-3.10 (m, 1H, H2\({}^{\prime}\)b), 2.74-2.67 (m, 2H, H11a,b), 2.15-2.05 (m, 1H, H1\({}^{\prime}\)a), 1.99-1.90 (m, 1H, H1\({}^{\prime}\)b), 1.76-1.68 (m, 2H, H10a,b), 1.66-1.57 (m, 2H, H8a,b) and 1.51-1.43 (m, 2H, H9a,b). \({}^{13}\)C NMR (101 MHz, CD\({}_{3}\)OD) 8 76.10 (C1), 74.44, 71.87, 71.23, 70.73, 70.63, 70.60, 70.32 and 70.17 (C3, C2, C4, C5, C6, C7, CH\({}_{2}\)CH\({}_{2}\)O- \(\times\) 6), 39.63 (C11), 38.06 (C2\({}^{\prime}\)), 29.45 (C8), 29.21 (C10), 25.63 (C9) and 24.20 (C1\({}^{\prime}\)). MS: \(m/z=882.2\) [M+H]\({}^{+}\). 2.2.13. 5-(N,N-Dimethylamino)-N-(2-(6-(1-thio-(5-(2-(2-(2-(2-hydroxyethyl)ethoxy)ethyl)))-amino-D-glucopyranosyl)-naphthalene-1-sulfonamide (dimer) **2**  
Compound **18** (10 mg, 0.023 mmol as monomer) was dissolved in MeOH; Et\({}_{3}\)N (10 \(\mu\)L) and dansyl chloride (16 mg, 0.06 mmol) were added and the reaction was stirred at r.t. The reaction was followed by TLC (EtOAc/MeOH 9:1 and EtOAc/MeOH/H\({}_{2}\)O/AcOH 5:5:1:1). After 10 h, the crude was purified by normal phase flash chromatography (silica gel, eluent: EtOAc/MeOH 8:2) and then with reverse phase C18 Cartridge, affording 6 mg (0.009 mmol, 39% yield) of compound **2**. \({}^{1}\)H NMR (500 MHz, CD\({}_{3}\)OD) 8 8.54 (t, J = 14.1 Hz, 1H, CH Ar), 8.36 (d, J = 8.7 Hz, 1H, CH Ar), 8.21 (dd, J = 7.3, 1.1 Hz, 1H, CH Ar), 7.59 (t, J = 7.7 Hz, 2H, CH Ar), 7.27 (d, J = 7.3 Hz, 1H, CH Ar), 3.86-3.77 (m, 1H, H1), 3.68-3.63 (m, 2H, H6a, CH\({}_{2}\)CH\({}_{2}\)O-), 3.62-3.55 (m, 10H, CH\({}_{2}\)CH\({}_{2}\)O-), 3.55-3.51 (m, 2H, H6b, CH\({}_{2}\)CH\({}_{2}\)O-), 3.49-3.42 (m, 3H, H2, H7a,b), 3.39-3.34 (m, 2H, H3, H5), 3.18-3.11 (m, 1H, H4), 3.00-2.91 (m, 2H, H2\({}^{\prime}\)a,b), 2.88 (s, 6H, (CH\({}_{3}\))\({}_{2}\)N-), 2.65 (t, J = 7.2 Hz, 2H, H11a,b), 1.77-1.71 (m, 2H, H1\({}^{\prime}\)a,b), 1.69-1.62 (m, 2H, H10a,b), 1.60-1.51 (m, 2H, H8a,b) and 1.47-1.39 (m, 4H, H9a,b). \({}^{13}\)C NMR (101 MHz, CD\({}_{3}\)OD) 8 152.4 (CqAr), 135.2 (CqAr), 131.18 (CH Ar), 130.9 (CqAr), 130.32 (CH Ar), 129.12 (CH Ar), 124.39 (CH Ar), 120.60 (CH Ar), 116.43 (CH Ar), 114.2 (CqAr), 75.23, 75.05, 73.52, 72.56 and 72.17 (C1, C2, C3, C4, C5), 72.93, 72.13, 71.92, 71.52, 71.50 and 71.30 (C7, CH\({}_{2}\)CH\({}_{2}\)O- x 6), 57.46 (C6), 48.58 (CH\({}_{3}\))\({}_{2}\)N-), 39.82 (C11), 41.30 (C2\({}^{\prime}\)), 29.78 (C8), 29.45 (C10), 26.12 (C\({}^{\prime}\)) and 25.23 (C9). MS: \(m/z=1348.8\) [M+H]\({}^{+}\), 1370.7 [M+Na]